Ensysce Biosciences Inc (ENSC)
$0.37
Performance
- $0.36$0.38$0.37
2.43%
Downside
Day's Volatility :4.01%
Upside
1.62%
- $0.35$2.06$0.37
5.38%
Downside
52 Weeks Volatility :83.0%
Upside
82.04%
Returns
| Period | Ensysce Biosciences Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -31.44% | 0.0% |
6 Months | -52.42% | 0.0% |
1 Year | -80.21% | 0.0% |
3 Years | -99.96% | -22.3% |
Highlights
Market Capitalization | 3.3M |
Book Value | $0.22 |
Earnings Per Share (EPS) | -2.65 |
Wall Street Target Price | 8.3 |
Profit Margin | 0.0% |
Operating Margin TTM | -1075.62% |
Return On Assets TTM | -131.94% |
Return On Equity TTM | -427.89% |
Revenue TTM | 1.4M |
Revenue Per Share TTM | 0.27 |
Quarterly Revenue Growth YOY | -62.9% |
Gross Profit TTM | -1.2M |
EBITDA | -24.2M |
Diluted Eps TTM | -2.65 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.43 |
EPS Estimate Next Year | -0.91 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 2143.24%
Technicals Summary
Sell
Neutral
Buy
Ensysce Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ensysce Biosciences Inc | -2.68% | -52.42% | -80.21% | -99.96% | -99.99% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ensysce Biosciences Inc | NA | NA | NA | -1.43 | -4.28 | -1.32 | NA | 0.22 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ensysce Biosciences Inc | Buy | $3.3M | -99.99% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Ensysce Biosciences Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 515.03K → 181.79K (in $), with an average decrease of 40.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -3.50M → -1.96M (in $), with an average increase of 35.4% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 117.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 169.2%
Institutional Holdings
Sabby Management LLC
2.83%Geode Capital Management, LLC
0.22%Vanguard Group Inc
0.22%UBS Group AG
0.15%Renaissance Technologies Corp
0.13%Tower Research Capital LLC
0.10%
Company Information
ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.
Organization | Ensysce Biosciences Inc |
Employees | 7 |
CEO | Dr. D. Lynn Kirkpatrick Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.37
-0.27%
Keyarch Acquisition Corp
$0.37
-0.27%
Connexa Sports Technologies Inc
$0.37
-0.27%
Us Value Etf
$0.37
-0.27%
First Wave Biopharma Inc
$0.37
-0.27%
Global X Msci Next Emerging
$0.37
-0.27%
Fat Projects Acquisition Corp
$0.37
-0.27%
Capital Link Global Fintech
$0.37
-0.27%
Applied Uv Inc
$0.37
-0.27%